Pfizer Inc. (PFE) Q4 2025 (USD): Adj. EPS 0.66 (exp. 0.58), Revenue 17.6bln (exp. 16.85bln); FY26 revenue view 59.5-62.5bln (exp. 61.94bln), FY26 EPS 2.80-3.00 (exp. 2.97)

Pfizer Inc. (PFE) Q4 2025 (USD): Adj. EPS 0.66 (exp. 0.58), Revenue 17.6bln (exp. 16.85bln); FY26 revenue view 59.5-62.5bln (exp. 61.94bln), FY26 EPS 2.80-3.00 (exp. 2.97)

Pfizer's Q4 2025 results exceeded expectations on both EPS and revenue, which is likely to bolster investor confidence in the company's growth trajectory. Additionally, the FY26 revenue and EPS guidance ranges suggest a solid outlook, though the upper bounds are only slightly above consensus estimates, indicating cautious optimism rather than a robust upward revision. This performance could positively impact sentiment in the pharma sector and influence PFE's stock trajectory in the near term.